Atrial fibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers. Clinical evidence suggests that antiarrhythmic therapy to restore and maintain sinus rhythm (rhythm control) can reduce adverse cardiovascular outcomes in patients with new-onset atrial fibrillation. As a result, a paradigm shift towards rhythm control over rate control therapy is emerging, increasing the clinical need for effective and safe antiarrhythmic drugs.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Saljic, A., Heijman, J. & Dobrev, D. Emerging antiarrhythmic drugs for atrial fibrillation. Int. J. Mol. Sci. 23, 4096 (2022).
Saljic, A., Heijman, J. & Dobrev, D. Recent advances in antiarrhythmic drug therapy. Drugs 83, 1147–1160 (2023).
Camm, A. J. et al. The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review. J. Am. Coll. Cardiol. 79, 1932–1948 (2022).
Schmidt, C. et al. Upregulation of K2P3.1 K+ current causes action potential shortening in patients with chronic atrial fibrillation. Circulation 132, 82–92 (2015).
Wiedmann, F. et al. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc. Res. 118, 1728–1741 (2022).
Holst, A. G. et al. Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial. Nat. Med. 30, 106–111 (2024).
Novartis Pharmaceuticals. Clinical trial report https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=18069 (accessed 20 January 2024).
Reiffel, J. A. et al. The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circ. Arrhythm. Electrophysiol. 8, 1048–1056 (2015).
Krisai, P. et al. Canakinumab after electrical cardioversion in patients with persistent atrial fibrillation: a pilot randomized trial. Circ. Arrhythm. Electrophysiol. 13, e008197 (2020).
Paasche, A. et al. Acute antiarrhythmic effects of SGLT2 inhibitors — dapagliflozin lowers the excitability of atrial cardiomyocytes. Basic Res. Cardiol. 119, 93–112 (2024).
Acknowledgements
F.W. received support from the German Cardiac Society, German Heart Foundation/German Foundation of Heart Research, Joachim-Herz Foundation and Health+Life Science Alliance Heidelberg Mannheim, including state funds approved by the State Parliament of Baden-Württemberg. C.S received support from the German Heart Foundation, German Center for Cardiovascular Research, German Ministry of Education and Research and Else-Kröner Fresenius Foundation. C.S. and F.W. are members of the CRC1425 and CRC1550, funded by the German Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.W. and C.S. have filed patent applications for TASK1-based gene therapy and for pharmacological TASK1 inhibition for the treatment of cardiac arrhythmias. C.S. has filed a patent application for interventional nanoparticle-based antiarrhythmic therapeutic strategies and has received research funding from Boehringer Ingelheim.
Rights and permissions
About this article
Cite this article
Wiedmann, F., Schmidt, C. Novel drug therapies for atrial fibrillation. Nat Rev Cardiol 21, 275–276 (2024). https://doi.org/10.1038/s41569-024-01004-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-024-01004-2